Diagnostic and Management Pathways for Pulmonary Carcinoid Tumours in the United Kingdom: Results from the National Lung Neuroendocrine Tumour Pathway Project

Table 2

Reported first-, second-, and third-line treatments for patients with advanced disease.

Treatments used (not mutually exclusive)	No. (%) of respondents (n = 27)
	First-line	Second-line	Third-line
SSA	17 (63%)	5 (19%)	2 (7%)
CT	3 (11%)	9 (33%)	11 (41%)
Surgery	6 (22%)	—	1 (4%)
mTOR inhibitor/targeted therapy	1 (4%)	7 (26%)	3 (11%)
RT	—	2 (7%)	1 (4%)
PRRT	—	3 (11%)	5 (19%)
Interferon	—	—	1 (4%)
Clinical trial	—	1 (4%)	1 (4%)
Not known/not applicable	3 (11%)	2 (7%)	5 (19%)

Respondents who reported that they refer patients to another centre or specialist for treatment. CT: chemotherapy; mTOR: mammalian target of rapamycin; PRRT: peptide receptor radionuclide therapy; RT: radiotherapy; and SSA: somatostatin analogue.